The DNPH1 Knockout CAL-27 Polyclonal Cells comprise a CRISPR/Cas9-edited polyclonal knockout population derived from the CAL-27 human tongue squamous cell carcinoma line through targeted disruption of the DNPH1 gene. This heterogeneous cellular pool provides a loss-of-function model that avoids clonal selection bias, enabling robust assessment of how DNPH1 ablation impacts nucleotide salvage and dNTP pool homeostasis in an oral cancer context.
CAL-27, established from a tongue squamous cell carcinoma of a 56-year-old male, is a widely recognized model of human oral squamous cell carcinoma (OSCC). The cells exhibit an epithelial phenotype and harbor mutations in TP53, recapitulating the genomic instability typical of aggressive oral tumors. This background makes CAL-27 particularly relevant for investigating the roles of nucleotide metabolism enzymes in cancer cell proliferation, invasion, and therapeutic resistance.
DNPH1 functions as a 2′-deoxynucleoside 5′-monophosphate hydrolase, catalyzing a crucial step in nucleotide salvage that regulates intracellular dNTP concentrations. Transcription of DNPH1 is directly activated by the c-Myc oncoprotein, which forms heterodimers with MAX to drive expression of genes supporting biomass accumulation. DNPH1 collaborates with related salvage factors including cytidine deaminase (CDA), dCTP pyrophosphatase 1 (DCTPP1), and thymidine kinase 1 (TK1) to fine?tune dNTP pools. This regulatory axis ensures adequate substrate availability for DNA polymerases during replication and repair, linking c-Myc signaling to genomic integrity.
Disrupting DNPH1 in CAL-27 cells is anticipated to impair nucleotide salvage, leading to imbalanced dNTP levels that provoke replication stress and compromised DNA repair. Such defects can sensitize cells to DNA-damaging agents and antimetabolites like gemcitabine, providing a platform to explore chemoresistance mechanisms. In OSCC, where c-Myc is frequently overexpressed, DNPH1 knockout may uncouple growth signaling from dNTP supply, thereby attenuating proliferation and highlighting a metabolic vulnerability in oral cancer cells.
This polyclonal knockout product is suited for a range of research applications, including quantitative dNTP profiling by HPLC, DNA damage assessment via phospho-??H2AX immunofluorescence, and examination of proliferative capacity using clonogenic and cell growth assays. The model can be employed to dissect c-Myc-dependent signaling networks through Western blotting and RT-qPCR, and to screen for drug sensitivity, e.g., to gemcitabine. Together, these tools enable detailed mechanistic studies of nucleotide metabolism in oral cancer. For additional information, contact Ascent Research.
